Novartis to Highlight Updated Data from the P-III (NATALEE) Study of Kisqali (Ribociclib) for Treating Early Breast Cancer (EBC) a...
Shots: Novartis will highlight 4yrs. post-hoc analysis from P-III (NATALEE) study...
Shots: Novartis will highlight 4yrs. post-hoc analysis from P-III (NATALEE) study...
Shots: Neurocrine has provided updates on the P-II (ERUDITE) trial assessing the s...
Shots: The P-III (
Shots: The
Shots: Bayer plans to highlight full results from the P-III (
Shots: The P-III (LIBERTY-CUPID Study C) trial assessed Dupixent + SoC (H1 antihis...
Incisive News in 3 Shots.